^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Nurdati (prolgolimab/nurulimab)

    i
    Other names: BCD-217, Anti-CTLA-4/Anti-PD-1 FDC, BCD 217, BCD217
    Associations

    News

    Trials
    Company:
    Biocad
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    NEO-MIMAJOR: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (clinicaltrials.gov)
    P3, N=410, Recruiting, Biocad
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • Nurdati (prolgolimab/nurulimab)
    almost2years
    OCTAVA: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (clinicaltrials.gov)
    P3, N=270, Recruiting, Biocad
    New P3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Nurdati (prolgolimab/nurulimab)
    almost2years
    OBERTON: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, Biocad | Unknown status --> Active, not recruiting | Trial completion date: Nov 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jul 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600
    |
    Nurdati (prolgolimab/nurulimab)
    over4years
    OBERTON: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=112, Recruiting, Biocad | Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Nov 2021
    Clinical • Enrollment open • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600
    |
    Forteca (prolgolimab) • Nurdati (prolgolimab/nurulimab)